RE:RE:RE:RE:RE:RE:RE:RE:DM- expirations of optionsfour, nice post but i must correct you on a number of items:
a) CEO's do matter, else why have them and if the CEO of RVX should be replaced he should be replaced, the issue IME tends to be incompetent CEO's and incompetent BoD's
b) re. FDA...21st century cures will not apply to current 208 trials, but it wil likely apply to any supposed maybed in the future ODD trial ...re. FDA trials, the SoP for the FDA as i understand it is 2 PIII "well-controlled" trials that confirm results, and 1 must be under direct FDA authority (so they could do BoM with FDA use it as part of a data package but still must do 1 PIII approved directly by the FDA)..and that IMO is the current problem RVX is desperately trying to get away with just 1 PIII and the FDA i suspect ain't going for it (nor should they as IMO 208+ is supposedly an improvement over current SoC and not in an "unmet need" situation)..and IMO profits from the US will exceed by 100% profits from the ROW so it really, really, really matters (chinee is irrelevant)
c) re. other stuff you post, i believe none of it if the "market" believed in RVX it would be much more highly valued...the various clinical failures, the goofy corporate stuff, the huge debt, etc. make RVX a very, very high risk investment...irrespective of what the rubes believe
regards